Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.

---

Copy For Citation

Sag S., Kaderli A. A., Yıldız A., Gul B. C., Özdemir B., Baran I., ...More

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, vol.45, pp.415-425, 2017 (Scopus)

• Publication Type: Article / Article
• Volume: 45
• Publication Date: 2017
• Doi Number: 10.5543/tkda.2017.80026
• Journal Name: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
• Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
• Page Numbers: pp.415-425
• Keywords: Aquaretic treatment, congestive heart failure, hyponatremia, tolvaptan, REDUCED EJECTION FRACTION, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, EVEREST TRIAL, PROGNOSTIC VALUE, DOUBLE-BLIND, INSIGHTS, REGISTRY, RATIONALE, BLOCKADE, OUTCOMES
• Bursa Uludag University Affiliated: Yes

Abstract

Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.